15126-06-4

Basic information

• Product Name: METHYL 4-HYDROXY-3-IODOBENZOATE
• Synonyms: METHYL 4-HYDROXY-3-IODOBENZOATE;4-HYDROXY-3-IODOBENZOIC ACID METHYL ESTER;Methyl 3-Iodo-4-hydroxybenzoate;2-Iodo-4-(methoxycarbonyl)phenol;Methyl 4-hydroxy-3-iodobenzoate 97%
• CAS NO: 15126-06-4
• Molecular Formula: C₈H₇IO₃
• Molecular Weight: 278.04
• Product Categories: C8 to C9;Carbonyl Compounds;Esters
• Mol File: 15126-06-4.mol

Chemical Properties

• Melting Point: 155-159 °C(lit.)
• Boiling Point: 292.7 °C at 760 mmHg
• Flash Point: 130.8 °C
• Appearance: White to pale brown/Crystal or Powder
• Density: 1.88 g/cm³
• Vapor Pressure: 0.00103mmHg at 25°C
• Refractive Index: 1.633
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 6.91±0.18(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: METHYL 4-HYDROXY-3-IODOBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 4-HYDROXY-3-IODOBENZOATE(15126-06-4)
• EPA Substance Registry System: METHYL 4-HYDROXY-3-IODOBENZOATE(15126-06-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 15126-06-4(Hazardous Substances Data)

Usage

Chemical Properties

Off White Powder

InChI:InChI=1/C8H7IO3/c1-12-8(11)5-2-3-7(10)6(9)4-5/h2-4,10H,1H3

Upstream product

• 67-56-1 methanol 
• 37470-46-5 4-hydroxy-3-iodobenzoic acid 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 32294-60-3 diphenyl ditelluride 
• 3337-66-4 methyl 4-hydroxy-3,5-diiodobenzoate 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 4253-10-5 methyl 3,5-diiodo-4-methoxybenzoate 
• 74-88-4 methyl iodide 
• 1571-72-8 3-amino-4-hydroxybenzoic acid 
• 99-96-7 4-hydroxy-benzoic acid 

Downstream Products

• 190067-52-8 2-t-butyl-benzofuran-5-carboxylic acid, methyl ester 
• 190067-53-9 methyl 2-phenylbenzo[b]furan-5-carboxylate 
• 69703-21-5 methyl 2-(2-hydroxypropan-2-yl)benzofuran-5-carboxylate 
• 195060-55-0 3-iodo-4-[2-oxo-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-ethoxy]benzoic acid methyl ester 
• 207865-33-6 4-[2-(3-Adamantan-1-yl-4-methoxy-phenyl)-2-oxo-ethoxy]-3-iodo-benzoic acid methyl ester 
• 207865-34-7 methyl 4-[2-(8,8-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2-oxoethoxy]-3-iodobenzoate 
• 207865-35-8 Methyl 3-iodo-4-[2-oxo-2-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethoxy]-benzoate 
• 551002-32-5 methyl 2-(4-methoxyphenyl)benzofuran-5-carboxylate 
• 156001-68-2 methyl 3-cyano-4-hydroxybenzoate 
• 784210-22-6 methyl 4-{[(4-chlorophenyl)sulfonyl]oxy}-3-iodobenzoate 
• 100725-29-9 3-iodo-4-phenoxybenzoic acid methyl ester 
• 882810-08-4 4-hydroxy-3-(1-hydroxy-3-methylbut-2-enyl)benzoic acid methyl ester 
• 869790-27-2 3-iodo-4-(2-aminophenoxy)benzoic acid methyl ester 
• 869790-29-4 3-iodo-4-(2-amino-4-cyanophenoxy)benzoic acid methyl ester 

Relevant articles and documents

CuLi2Cl4 catalysed cross-coupling strategy for the formal synthesis of the diterpenoid (+)-subersic acid from (?)-sclareol

A CuLi2Cl4-catalysed regioselective cross-coupling is used in a key step leading to the concise synthesis of (+)-subersic acid with an overall yield of 25.7% from commercially available (-)-sclareol. The coupled product 15-(2-methoxy-5-carbomethoxy)phenyl-labda-8(9),13Ediene was obtained in 62% yield under CuLi2Cl4 conditions starting from 2-iodo-4-carbomethoxyanisole and 15-acetoxy-labda-8(9),13Ediene. These were derived from 4-hydroxybenzoic acid and (-)-sclareol respectively. The 15-(2-methoxy-5-carbomethoxy)phenyl-labda- 8(9),13E-diene was easily transformed into (+)-subersic acid by demethylation of the phenol ether and ester. This cross-coupling strategy showed a good functional group tolerance and various (+)-subersic acid derivatives were obtained in moderate yields.

Palladium-Catalyzed Chemoselective Oxidative Addition of Allyloxy-Tethered Aryl Iodides: Synthesis of Medium-Sized Rings and Mechanistic Studies

This Letter describes a Pd-catalyzed Tsuji-Trost-type/Heck reaction with allyloxy-tethered aryl iodides and aziridines. The strategy provides efficient access to benzannulated medium-sized rings via intermolecular cyclization. The substrate aryl iodide ha

Biomimetic carbene cascades enabled imine derivative migration from carbene -bearing thiocarbamates

Inspired by the body circulation of Omeprazole (irreversible proton pump inhibitor), we disclose the carbene-triggered cascades for the synthesis of 2-aminobenzofuran derivatives from N-sulfonyl-1,2,3-triazoles or benzothioazole-bearing thiocarbamates, which represents an unprecedented imine derivative migration process. Furthermore, the desulfurizing reagent-free Barton-Kellogg-type reactions starting from N-sulfonyl-1,2,3-triazoles have also been achieved for the first time, and elemental sulfur is confirmed as a byproduct during this transformation. Both experimental data and DFT calculations further thoroughly explained the unique reactivity.

Efficient and sustainable laccase-catalyzed iodination of: P -substituted phenols using KI as iodine source and aerial O2 as oxidant

The laccase-catalyzed iodination of p-hydroxyarylcarbonyl- and p-hydroxyarylcarboxylic acid derivatives using KI as iodine source and aerial oxygen as the oxidant delivers the corresponding iodophenols in a highly efficient and sustainable manner with yields up to 93% on a preparative scale under mild reaction conditions.

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.

N-Iodosuccinimide (NIS) in Direct Aromatic Iodination

N-Iodosuccinimide (NIS) in pure trifluoroacetic acid (TFA) offers a time-efficient and general method for the iodination of a wide range of mono- and disubstituted benzenes at room temperature, as demonstrated in this paper. The starting materials were generally converted into mono-iodinated products in less than 16 hours at room temperature, without byproducts. A few deactivated substrates needed addition of sulfuric acid to increase the reaction rate. Another exception was methoxybenzenes that preferentially were iodinated by NIS in acetonitrile with only catalytic amounts of TFA.

OXADIAZOLE MODULATORS OF S1P METHODS OF MAKING AND USING

The invention is directed to Compounds of Formula (I): wherein each variable is defined herein, as well as methods of making and using the compounds as agonists of S1P1 and/or S1P5 for instance for treating graft versus host disease and autoimmune diseases.

One-pot syntheses of 2,6-diiododiaryl ethers from para-EWG-substituted phenols by diacetoxyiodobenzene

2,6-Diiododiaryl ethers are not only useful blocks to construct substituted diaryl ethers but are also characteristic drug precursors. In this research, a one-pot tandem oxidation of phenols substituted with electron-withdrawing group at the para position by excess diacetoxyiodobenzene is proven as a novel and efficient method for preparing 2,6-diiododiaryl ethers. Using this method, three new 2,6-diiododiaryl ethers, namely, methyl 3,5-diiodo-2-methoxy-4-phenoxybenzoate (2), methyl 3,5-diiodo-4-phenoxybenzoate (6), and 1-(2,6-diiodo-4-nitrophenoxy)benzene (7) were readily obtained from the corresponding phenols, and the yields were good.

Heterocyclic modulators of cannabinoid receptors

Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are a

NEUROPROTECTIVE CB2 RECEPTOR AGONISTS

A method of treating or preventing a neuroinflammatory and/or neurodegenerative disease in a subject by administering a pharmaceutically effective amount of a CB2 receptor agonist is described. The CB2 receptor agonist can be a compo